Company: PFSA
Filing Date: 2025-10-09
Form Type: S-1
Source: 0001213900-25-097860
Chunk: 394

Company: Profusa, Inc.
Filing Date: 2025-10-09
Form: S-1
Chunk 394
---
 Company’s common stock as consideration thereunder. On July 11, 2025, the Closing was completed. In connection with the Closing, the Company changed its name to “Profusa, Inc.” F-101 NORTHVIEW ACQUISITION CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Note 6 — Commitments and Contingencies(cont.)

Advisory Agreements

On December 19,
2024, the Company engaged A.G.P to serve as the placement agent in connection with a proposed business combination transaction. The
Company shall pay to A.G.P. a cash fee (the “Cash Fee”) equal to % in a convertible note offering, note, or other
similar equity-linked offerings, and shall be calculated from the face value of notes issued, which is payable at the close of a
Business Combination. On June 17, 2025, the Company entered a settlement agreement with A.G.P. for the Cash Fee of $
related to the debt private placement (the “Offering”) that was issued at the Closing. Pursuant to the settlement
agreement, as a result of the Business Combination, the Company paid A.G.P. $ at the Closing and the remaining $ of
the fees was deferred and due on the earlier of (i) the second tranche of the debt private placement being issued and
(ii) December 31, 2025. The Company also agreed to reimburse A.G.P. $ for expenses incurred in connection with the
offering.

On June 15, 2023, the
Company engaged the Benchmark Company LLC (“Benchmark”) to provide advisory services related to the Business Combination and
the Convertible Notes. The Company was to pay Benchmark at the closing of the Business Combination an advisory fee of $ in two
tranches. The first tranche will be $ earned upon the closing of the Business Combination in the surviving public entity’s
common stock (“Tranche 1”). The number of shares to be issued is calculated on the 30 day following the
Closing by dividing $ and the trailing 5-day VWAP of the Company’s common stock as calculated by Bloomburg with a minimum
price of $. The second tranche will be $, at the Company’s option, in either cash or in the surviving entity’s
common shares calculated by dividing $ by the lowest trailing 5-day VWAP in the prior 30 days (“Tranche 2”). Upon
funding of the Convert